FIRST PRINCIPLES STRATEGIES LLC ON BEHALF OF IMMIX BIOPHARMA, INC

Lobbying client · District of Columbia · filed 2025 to 2026

Clinical State biotechnology development

$20,000 Reported spend

3 Filings counted

1 Outside firm hired

0 Bills named

Spend is reported income plus in-house expenses across 3 filings. Everything on this page comes from one LDA client record (75699), filed by the registrant listed below.

Who filed for this client 1

YC CONSULTING, LLC $20,000 Outside firm · 3 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Reported by year 2 years

2026 $20,000 2 filings
2025 $0 1 filing

Issues lobbied 1

Health Issues 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

Food & Drug Administration (FDA) 1
HOUSE OF REPRESENTATIVES 1

Recent filings 3 total

Q3 report

YC CONSULTING, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · $20,000 income · posted Oct 21, 2026

View → Registration amendment

YC CONSULTING, LLC

3rd Quarter 2026 (July 1 - Sep 30) · posted Oct 21, 2026

View → Registration

YC CONSULTING, LLC

3rd Quarter 2025 (July 1 - Sep 30) · posted Oct 20, 2026

View →

Keep going

Filings through October 21, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.